Mortality outcomes of extended-spectrum β-lactamase in bacteremia with carbapenems and other antibiotics: A systematic review
Abstract
, and reviewed evidence on carbapenem-sparing regimens to avoid carbapenem use in treating ESBL infections, focusing on patients with bacteremia. This study analyzed 30-day all-cause mortality outcomes in adult patients over 18 years treated with carbapenem compared to other antibiotics for bloodstream infections caused by ESBL using Scopus, PubMed, and Sage Journal databases from 2015 to 2024, using pooled risk ratios and 95% confidence intervals for all outcomes. Eight studies found no significant differences between groups receiving carbapenems and other antibiotics. However, carbapenems were found to have a higher 30-day all-cause mortality rate than comparative antibiotics for ESBL in bacteremia. Two studies reported lower 30-day all-cause mortality rates when using carbapenems. There was no significant correlation between antibiotic use and ESBL-related mortality in bacteremia patients. Most carbapenem therapy users had a higher mortality rate than those using other antibiotics; however, the difference was not statistically significant.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.